(Q56985985)

English

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

article by Frédéric Peyrade et al published May 2011 in Lancet Oncology Commission

In more languages

Statements

scholarly article

0 references

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial (English)

0 references

0 references

phase II clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

Catherine Thieblemont

3

object named as

Catherine Thieblemont

0 references

author name string

Frédéric Peyrade

1

0 references

Fabrice Jardin

2

0 references

Antoine Thyss

4

0 references

Jean-François Emile

5

0 references

Sylvie Castaigne

6

0 references

Bertrand Coiffier

7

0 references

Corinne Haioun

8

0 references

Serge Bologna

9

0 references

Olivier Fitoussi

10

0 references

Gérard Lepeu

11

0 references

Christophe Fruchart

12

0 references

Dominique Bordessoule

13

0 references

Michel Blanc

14

0 references

Richard Delarue

15

0 references

Maud Janvier

16

0 references

Bruno Salles

17

0 references

Marc André

18

0 references

Marion Fournier

19

0 references

Philippe Gaulard

20

0 references

Hervé Tilly

21

0 references

language of work or name

0 references

publication date

May 2011

0 references

Lancet Oncology Commission

0 references

12

0 references

5

0 references

460-8

0 references

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-Hodgkin's malignant lymphomas in patients older than 80. 70 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-Hodgkin's lymphoma in patients 80 years of age or older

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Is lymphoma occurring in the elderly the same disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Aggressive Chemotherapy for Diffuse Histiocytic Lymphoma in the Elderly: Increased Complications with Advancing Age

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The Lawton instrumental activities of daily living scale

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognos

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluating the older patient with cancer: understanding frailty and the geriatric assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Performance status is the single most important prognostic factor in lymphoma patients aged greater than 75 overriding other prognostic factors such as histology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive geriatric assessment for older patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted treatment and new agents in diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970069-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70069-9

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56985985&oldid=1783755911"